Steven Kregel, PhD, MS

Title & Department

Research Assistant Professor


College of Medicine

Research Program

Cancer Biology (CB)

Phone: 847-293-1399


Prostate cancer is one of the leading causes of cancer-related deaths, but treatment options for men with advanced, metastatic disease are limited. Development of novel therapeutics for metastatic castration resistant prostate cancer (mCRPC) depends on improving the murine models of this disease, adapting and modeling currently relevant therapies like novel immunotheraputics, and identifying the oncogenic drivers of late state disease; particularly after standard-of-care Androgen Receptor (AR) targeted therapies fail. My research applies multiple strategies, from clinically relevant in vivo models to mechanistic cell biology, and systemic unbiased genomic studies to identify the molecular underpinnings of the responses and failures of prostate cancer therapies and the basic processes of cellular growth. AR signaling is important in both cancer cells and the stromal cells of the tumor microenvironment, and by developing new mouse and genomic models to study this, we can identify new downstream drug targets for both late-stage cancer and the stromal cells and be able to preclinically test the feasibility of drug targets for mCRPC therapy.


PhD, University of Chicago

Disease Focus

Prostate Cancer

Research Keywords

Prostate Cancer; Androgen Receptor; Immunotherapy; Therapeutic Resistance; Protac; Tumor Immunology; Nkx3.1

Published Research

PubMed Search

Translate »